Table 1. Demographic, Laboratory, Clinical and Tumor Staging Characteristics of 151 Patients with HCC in Compensated Cirrhosis Treated with RFA.
| Characteristic | Child-Pugh A (n = 122) | Child-Pugh B (n = 29) |
| Age – years | 67±7.5 | 67±5.4 |
| Male – no. (%) | 82 (67) | 20 (69) |
| Etiology of Cirrhosis-no. (%) | ||
| Anti-HCV positivity | 108 (88.4) | 25 (86.4) |
| HBsAg positivity | 10 (8.2) | 1 (3.4) |
| Alcohol abuse | 3 (2.6) | 1 (3.4) |
| NAFLD | 1 (0.8) | 2 (6.8) |
| Hepatic Encephalopathy-no. (%) | ||
| None | 122 (100) | 29 (100) |
| Ascites – no. (%) | ||
| None | 122 (100) | 29 (100) |
| Albumin – g/dl | 3.7±0.5 | 3.2±0.4 |
| International Normalised Ratio | 1.10±0.12 | 1.2±1.5 |
| Total Bilirubin – mg/dl | 1.2±0.9 | 2.1±0.5 |
| Platelet × 103/ mmc | 105±58 | 72±32 |
| Creatinine-mg/dl | 0.8±0.3 | 0.9±0.3 |
| MELD Score | 9.0±1.9 | 9.0±2.1 |
| Oesophageal varices – no. (%) | ||
| None | 53 (43.5) | 5 (17.2) |
| F1 | 48 (39.3) | 16 (55.2) |
| F2/F3 | 21 (17.2) | 8 (27.6) |
| Portal Vein Thrombosis – no. (%) | ||
| None | 122 (100) | 29 (100) |
| AFP - ng/mL | 75±115 | 132±633 |
| Number of Nodules (%) | ||
| 1 | 90 (73.3) | 23 (79.3) |
| 2 | 27 (22) | 5 (17.2) |
| 3 | 5 (4.7) | 1 (3.5) |
| Tumor size– no. (%) | ||
| 3 cm | 103 (84.4) | 25 (86.2) |
| >3 cm | 19 (15.6) | 4 (13.8) |
Note. Values are mean ± SD.
Abbreviations: IU, international units; AFP, alpha fetoprotein; HCV, hepatitis C virus; HBV, hepatitis B virus; NAFLD, Nonalcoholic fatty liver disease; MELD, Model for End-Stage Liver Disease.